Monopar Receives Clearance to Move Forward with Phase 1 Therapeutic Trial
Monopar Therapeutics Inc. (Nasdaq: MNPR), a company in the clinical stage of developing radiopharmaceuticals, has announced today that it has obtained clearance from the Human Research Ethics Committee (HREC) in Australia to begin a Phase 1 therapeutic trial for its innovative radiopharmaceutical, MNPR-101-Lu.
Overview of MNPR-101-Lu
MNPR-101-Lu is a combination of the therapeutic radioisotope lutetium-177 (Lu-177) and Monopar’s proprietary first-in-class humanized monoclonal antibody, MNPR-101. This antibody is specifically designed to target the urokinase plasminogen activator receptor (uPAR). The Phase 1 clinical trial for MNPR-101-Lu will focus on patients with advanced solid tumors and will serve as a therapeutic follow-up to the ongoing MNPR-101-Zr imaging and dosimetry clinical trial.
Insights from Preclinical Studies
Preliminary results from studies on MNPR-101-Lu are encouraging. In a 90-day efficacy study using a human pancreatic cancer xenograft mouse model, MNPR-101-Lu showed significant antitumor effects following a single injection, successfully eliminating tumors for the entire duration of the study.
Therapeutic Effectiveness and Future Prospects
Imaging data obtained from the human pancreatic cancer xenograft mouse model further supports the strong therapeutic impact of MNPR-101-Lu after just one injection. This data highlights the high specificity and sustained uptake of MNPR-101-Lu within tumors compared to normal tissue.
“We are thrilled to have received HREC clearance and are optimistic about the potential of MNPR-101-Lu to deliver significant clinical benefits to patients with uPAR-positive tumors. Many of the most aggressive and deadly cancers, such as triple-negative breast cancer and pancreatic cancer, express uPAR,” stated Chandler Robinson, MD, Monopar’s Chief Executive Officer. “We are eager to commence the trial as soon as possible.”
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage company dedicated to developing innovative cancer treatments, including the Phase 1-stage MNPR-101-Zr for imaging advanced cancers and the late preclinical-stage MNPR-101-Lu and MNPR-101-Ac225 for treating advanced cancers. The company also has early development programs targeting solid tumors. For further details, visit: www.monopartx.com.
Frequently Asked Questions
What is the focus of the MNPR-101-Lu trial?
The MNPR-101-Lu trial aims to assess the effectiveness of a new radiopharmaceutical in treating patients with advanced solid cancers.
What components make up MNPR-101-Lu?
MNPR-101-Lu is made by combining the therapeutic radioisotope lutetium-177 (Lu-177) with a proprietary humanized monoclonal antibody known as MNPR-101.
What preclinical studies have been performed?
A 90-day efficacy study using a human pancreatic cancer xenograft mouse model demonstrated lasting antitumor effects from a single dose of MNPR-101-Lu.
What potential benefits does MNPR-101-Lu offer?
MNPR-101-Lu is anticipated to provide significant clinical benefits for patients with tumors that express uPAR.
Who are Monopar Therapeutics?
Monopar Therapeutics is a clinical-stage company focused on creating innovative cancer treatments, including various radiopharmaceuticals targeting different cancer types.
